Clinical Safety of a High Dose of Phycocyanin-Enriched Aqueous Extract from Arthrospira (Spirulina) platensis: Results from a Randomized, Double-Blind, Placebo-Controlled Study with a Focus on Anticoagulant Activity and Platelet Activation.
Clinical Safety of a High Dose of Phycocyanin-Enriched Aqueous Extract from Arthrospira (Spirulina) platensis: Results from a Randomized, Double-Blind, Placebo-Controlled Study with a Focus on Anticoagulant Activity and Platelet Activation.
复制标题
DOI：
10.1089/jmf.2015.0143
复制
发表时间：
2016-07
影响因子：
2.4
通讯作者：
Benson KF
中科院分区：
文献类型：
--
作者：
Jensen GS;Drapeau C;Lenninger M;Benson KF
本研究的目的是评估每天食用含有高剂量藻蓝蛋白的水蓝藻提取物（ACE）的抗凝血活性和血小板活化的安全性。采用随机、双盲、安慰剂对照研究设计，24名男性和女性在知情同意后入组，每天服用ACE （2.3 g/天）或安慰剂，持续2周。ACE剂量相当于每天1克藻蓝蛋白，根据美国食品和药物管理局公认安全（GRAS）的最高剂量选择。服用ACE并没有改变血小板活化（p -选择素表达）或血清p -选择素水平。活化部分凝血活酶时间、凝血酶凝血时间或纤维蛋白原活性均未见变化。血清天冬氨酸转氨酶（AST）水平在服用ACE 2周后显著降低（P < 0.05）。001)，与安慰剂相比，没有看到任何变化；2周时两组间AST水平差异有统计学意义（P < 0.02）。服用ACE组谷丙转氨酶（ALT）水平降低（P < .08）。以前的研究表明，每天服用1克ACE可以减轻慢性疼痛。在这项研究中，2.3 g/d的较高剂量与休息和体力活动时慢性疼痛的显著减少相关（P < 0.05）。在抗凝血活性和血小板激活状态方面，ACE的使用显示出安全性，并能快速有力地缓解慢性疼痛。AST和ALT降低提示肝功能和代谢改善。
The goal for this study was to evaluate safety regarding anticoagulant activity and platelet activation during daily consumption of an aqueous cyanophyta extract (ACE), containing a high dose of phycocyanin. Using a randomized, double-blind, placebo-controlled study design, 24 men and women were enrolled after informed consent, and consumed either ACE (2.3 g/day) or placebo daily for 2 weeks. The ACE dose was equivalent to ∼1 g phycocyanin per day, chosen based on the highest dose Generally Recognized as Safe (GRAS) by the U.S. Food and Drug Administration. Consuming ACE did not alter markers for platelet activation (P-selectin expression) or serum P-selectin levels. No changes were seen for activated partial thromboplastin time, thrombin clotting time, or fibrinogen activity. Serum levels of aspartate transaminase (AST) showed a significant reduction after 2 weeks of ACE consumption (P < .001), in contrast to placebo where no changes were seen; the difference in AST levels between the two groups was significant at 2 weeks (P < .02). Reduced levels of alanine transaminase (ALT) were also seen in the group consuming ACE (P < .08). Previous studies showed reduction of chronic pain when consuming 1 g ACE per day. The higher dose of 2.3 g/day in this study was associated with significant reduction of chronic pain at rest and when physically active (P < .05). Consumption of ACE showed safety regarding markers pertaining to anticoagulant activity and platelet activation status, in conjunction with rapid and robust relief of chronic pain. Reduction in AST and ALT suggested improvement in liver function and metabolism.